Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Farouque, J. Tremmel, Farshad Shabari, M. Aggarwal, W. Fearon, M. Ng, M. Rezaee, A. Yeung, David Lee (2005)
Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices.Journal of the American College of Cardiology, 45 3
B. Reeves, R. Ascione, M. Chamberlain, G. Angelini (2003)
Effect of body mass index on early outcomes in patients undergoing coronary artery bypass surgery.Journal of the American College of Cardiology, 42 4
Stephen Ellis, J. Elliott, M. Horrigan, R. Raymond, G. Howell (1996)
Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention.The American journal of cardiology, 78 6
E. Calle, M. Thun, Jennifer Petrelli, C. Rodríguez, C. Heath (1999)
Body-mass index and mortality in a prospective cohort of U.S. adults.The New England journal of medicine, 341 15
J. Velianou, B. Strauss, C. Kreatsoulas, D. Pericak, M. Natarajan (2000)
Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: In‐hospital and six‐month outcomesCatheterization and Cardiovascular Interventions, 51
J. Sowers (2003)
Obesity as a cardiovascular risk factor.The American journal of medicine, 115 Suppl 8A
Shelina Jamal, F. Shrive, W. Ghali, M. Knudtson, M. Eisenberg (2003)
In-hospital outcomes after percutaneous coronary intervention in Canada: 1992/93 to 2000/01.The Canadian journal of cardiology, 19 7
M. Natarajan, C. Kreatsoulas, J. Velianou, S. Mehta, D. Pericak, D. Goodhart (2004)
Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions.The American journal of cardiology, 93 6
Arya Sharma, T. Pischon, S. Hardt, I. Kunz, F. Luft (2001)
Hypothesis: β-Adrenergic Receptor Blockers and Weight GainHypertension, 37
A. Lincoff, N. Kleiman, K. Kottke-Marchant, E. Maierson, K. Maresh, K. Wolski, E. Topol (2002)
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).American heart journal, 143 5
A. Lincoff, J. Bittl, R. Harrington, F. Feit, N. Kleiman, J. Jackman, I. Sarembock, D. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr, E. Cohen, A. Betriu, W. Desmet, D. Kereiakes, W. Rutsch, R. Wilcox, P. Feyter, A. Vahanian, E. Topol (2003)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.JAMA, 289 7
H. Gurm, D. Brennan, J. Booth, J. Tcheng, A. Lincoff, E. Topol (2002)
Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox).The American journal of cardiology, 90 1
B. Powell, R. Lennon, A. Lerman, M. Bell, P. Berger, S. Higano, D. Holmes, C. Rihal (2003)
Association of body mass index with outcome after percutaneous coronary intervention.The American journal of cardiology, 91 4
Jamal Jamal, Shrive Shrive, Ghali Ghali (2003)
Canadian Cardiovascular Outcomes Research Team (CCORT). In‐hospital outcomes after percutaneous coronary intervention in Canada: 1992/93–2000/01Can J Cardiol, 19
G. Niccoli, A. Banning (2002)
Heparin dose during percutaneous coronary intervention: how low dare we go?Heart, 88
Brener Brener, Moliterno Moliterno, Lincoff Lincoff (2004)
Relationship between activated clotting time and ischemic or hemorrhagic complications: Analysis of 4 recent randomized clinical trialsCirculation, 110
H. Gurm, P. Whitlow, K. Kip (2002)
The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI).Journal of the American College of Cardiology, 39 5
A. Must, Jennifer Spadano, E. Coakley, A. Field, G. Colditz, W. Dietz (1999)
The disease burden associated with overweight and obesity.JAMA, 282 16
Sharma Sharma, Pischon Pischon (2001)
Hypothesis: Beta‐adrenergic receptor blockers and weight gain: A systematic analysisHypertension, 37
T. Pischon, Arya Sharma (2001)
Use of beta‐blockers in obesity hypertension: potential role of weight gainObesity Reviews, 2
S. Brener, D. Moliterno, A. Lincoff, S. Steinhubl, K. Wolski, E. Topol (2004)
Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications: Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary InterventionCirculation, 110
E. Potapov, M. Loebe, S. Anker, J. Stein, S. Bondy, B. Nasseri, R. Sodian, H. Hausmann, R. Hetzer (2003)
Impact of body mass index on outcome in patients after coronary artery bypass grafting with and without valve surgery.European heart journal, 24 21
L. Gruberg, N. Weissman, R. Waksman, S. Fuchs, R. Deible, E. Pinnow, Lanja Ahmed, K. Kent, A. Pichard, W. Suddath, L. Satler, J. Lindsay (2002)
The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?Journal of the American College of Cardiology, 39 4
A. Sharma (2003)
Obesity and cardiovascular risk.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 13 Suppl A
Objectives: To evaluate the effect of body mass index (BMI) on in‐hospital outcomes in patients undergoing percutaneous coronary intervention (PCI) at a tertiary care hospital center in Ontario, Canada. Background: Obesity is present in a large population of patients undergoing revascularization with PCI. Methods: Retrospective analysis of 4,631 patients aged 62.0 ± 12 years, stratified by BMI into five groups: nonobese (<25 kg/m2); overweight (25–29.9 kg/m2); class I obese (30–34.9 kg/m2); class II obese (35–39.9 kg/m2); and class III obese (≥40 kg/m2). Results: A BMI >25 kg/m2 was present in 79% of patients, and 35% were obese (BMI ≥30 kg/m2). Obese patients, particularly the class III obese, were significantly younger and had higher prevalence of diabetes, hypertension, and dyslipidemia (P < 0.0001). After adjustment for several covariates, lower BMI was independently associated with higher risk of major bleeding requiring transfusion (adjusted odds ratio (OR)= 1.40, 95% confidence interval (CI) 1.04–1.88, P = 0.025), and femoral hematoma (adjusted OR = 1.14, 95% CI 1.05–1.25, P = 0.003) in lean (<20 kg/m2) and normal BMI (20–24.9 kg/m2) patients. Obesity was not associated with death, myocardial infarction, repeat PCI, coronary artery bypass grafting, or major adverse cardiac event. Conclusions: Obesity is not associated with increased risk of adverse postprocedural in‐hospital outcomes. These findings, however, do not discount the need for sustained efforts in secondary prevention of obesity and its consequences.
Journal of Interventional Cardiology – Wiley
Published: Oct 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.